Activating a protein to make immunotherapy more effective for neuroblastoma
Professor Aymen Al-Shamkhani at the University of Southampton hopes to test a way to recruit immune cells into neuroblastoma tumours, making immunotherapy more effective.
Investigating an immunotherapy combination treatment for neuroblastoma
Professors Suzanne Turner, Anna Philpott and Aditi Vedi at the University of Cambridge will test a new combination treatment for neuroblastoma that could make current immunotherapies more effective.
Evaluation and optimization of drug combinations that kill neuroblastoma cancer cells
Professor Karim Malik aims to test a new combination of drugs that can eliminate neuroblastoma cells.
Using a DNA molecule as a new and safer treatment for neuroblastoma
Professor Arturo Sala will test a promising new adult cancer treatment in neuroblastoma to find a kinder and more effective treatment options.
Helping immunotherapy work better for children with neuroblastoma by reprogramming the tumour environment
Professor James Arnold is creating a new type of immunotherapy that can fight solid tumours and make it easier for the immune system to help.
Reading critical changes in neuroblastoma’s genetic messages
Dr Jodie Bojko at the University of Bristol hopes to understand how genetic instructions are altered in neuroblastoma, and how this impacts the cancer.
Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Creating advanced models to test new treatments for malignant rhabdoid tumours
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.